Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Download as PPTX, PDF12 likes3,078 views
This document provides an overview of immunohistochemistry markers that can help diagnose various salivary gland and head and neck tumors. It discusses the cell types that stain positively for different markers in normal salivary gland tissue and then examines the immunohistochemistry profiles of tumors like acinic cell carcinoma, mammary analogue secretory carcinoma, mucoepidermoid carcinoma, myoepithelial carcinoma, salivary duct carcinoma, adenoid cystic carcinoma, and polymorphous low-grade adenocarcinoma. Having an understanding of the typical marker expression in these tumors can aid pathologists in making accurate diagnoses.
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
- 1. Thanks to my resident Dr. Babar Yasin for making this presentation. JOURNEL CLUB PRESENTATION Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors.
- 2. Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors Shaobo Zhu, MD; Conrad Schuerch, MD; Jennifer Hunt, MD
- 3. Background: 34 benign and malignant salivary gland epithelial tumors according to the 2005 classification of the World Health Organization. Diverse morphology and overlapping histologic features. Immunohistochemistry is an adjunct tool to identify the cellular differentiation and assign correct classifications.
- 4. 3 major pairs of salivary glands and many minor salivary glands. The glands are composed of acini (serous, mucinous, and mixed) and ducts (intercalated, striated, and excretory). The acini and intercalated duct are surrounded by myoepithelial cells. The striated duct and excretory duct are surrounded by basal cells. Most salivary gland tumors originate from acinar/ductal epithelial cells (luminal cells) and/or myoepithelial/basal cells (abluminal cells).
- 5. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes tumors pleomorphic adenoma, epithelial myoepithelial carcinoma, and adenoid cystic carcinoma. Some tumors demonstrate other unique cellular differentiation, such as sebaceous adenoma/carcinoma, lymphadenoma, and mucoepidermoid carcinoma.
- 6. The acinar/ductal epithelial cells are: Positive for keratins (CK7 and CAM 5.2) and epithelial membrane antigen (EMA). They are focally positive or negative for high molecular-weight keratins (HMWKs; CK5/6 and 34bE12) Negative for p63, myoid markers (smooth muscle myosin heavy chain, smooth muscle actin, calponin), and CK20
- 8. Myoepithelial cells: Positive for p63, myoid markers, vimentin, S100, and HMWKs (CK5/6, 34bE12), Weak expression for CK7 and CAM 5.2 No expression for EMA.
- 9. Basal cells: Positive for p63 and HMWKs (CK5/6, 34bE12) Weakly positive or negative for CK7, CAM 5.2 and myoid markers (SMMHC, SMA, calponin) Negative for CK20, vimentin, S100, and EMA. (p63 also stains squamous epithelium)
- 10. A, Calponin. B, SMA. C, SMHC. D, Cytokeratin 5/6. E, p63. F, S100
- 11. SOX10 expression SOX10-positive tumors 1) Acinic cell carcinomas 2) Adenoid cystic carcinomas 3) Epithelial-myoepithelial carcinomas 4) Myoepithelial carcinomas 5) Pleomorphic adenomas SOX10-negative tumors 1) Salivary duct carcinomas 2) Mucoepidermoid carcinomas 3) Squamous cell carcinomas 4) Oncocytic carcinomas/oncocytomas 5) Warthin tumors
- 13. Demonstrates both serous acinar and intercalated ductal epithelial differentiation. Express CK7 and CAM 5.2 Negative for p63 and CK20, myoid markers. Positive for DOG1. (DOG1 with PAS can be used to distinguish it from mammary analogue secretory carcinoma)
- 14. Mammary Analogue Secretory Carcinoma Histologically, immunohistochemically, and genetically similar to secretory carcinoma of the breast. The tumor has a t(12;15)(p13;q25) ETV6-NTRK3 translocation that is also present in breast secretory carcinoma.
- 16. Positive for S100, mammaglobin, CK7, CK8, CK18, CK19, 34bE12, EMA, GCDFP-15, GATA3, STAT5a, MUC1, MUC4, and vimentin. Basal cell/myoepithelial cell markers usually do not show expression in the tumor. Negative for androgen receptor, ER, PR, HER2/neu. The MIB-1 indices range between 5% and 28%.46
- 17. Acinic cell carcinoma Mammary analogue secretory carcinoma CK8, CK 19 NEGATIVE POSITIVE GCDFP-15, Mammoglonin RARELY POSITIVE POSITIVE MUC4, S100 NEGATIVE POSITIVE
- 18. mammaglobin and S100 expression can be seen in polymorphous low-grade adenocarcinomas (60%) and adenoid cystic carcinomas (13.3%). However both these tumors are positive for p63 and negative for GCDFP-15.
- 20. Positive for CK5, CK6, CK7, CK8, CK14, CK18, CK19, EMA, CEA, and p63 CK20, SMA, muscle specific actin (MSA), and S100.
- 21. Strong staining for p63 helps differentiating Mucoepidermoid carcinoma from acinic cell carcinoma, oncocytoma and oncocytic carcinoma and mammary analogue secretory carcinoma.mmary analogue secretory carcinoma
- 23. Immunoreactivity for both keratins and at least 1 myoepithelial marker is required for the diagnosis. vimentin, calponin, S100, CK AE1/3, 34bE12, CAM 5.2, EMA caldesmon, SMA, MSA, GAFP Calponin is the most sensitive and specific marker to identify myoepithelial differentiation. A panel including CK AE1/3, CAM 5.2, CK5/6, calponin, SMA, S100, and vimentin, can be helpful to make an accurate diagnosis.
- 24. Markers for Salivary Gland Tumors With Clear Cell Differentiation ACC MEC MC EMC OC/OCA CCC p63 _ + + + outer layer Scant peripheral + Calponin /SMA/S MMHC _ _ + + outer layer _ _ CK7/CAM 5.2 + _ +/- + inner layer + + SOX10 + _ + + _
- 26. AR, GCDFP-15, GATA3, CK AE1/3, CK7, 34bE12, CEA, and EMA. Ki-67 expression markedly increased. The immunophenotype AR+/ER-/PR-/GCDFP+ is characteristic of salivary duct carcinoma, but it does not completely exclude metastasis from the breast, which might also be AR+, ER/PR – 80% of salivary duct carcinomas show HER2/ neu and p53 overexpression, which correlates to poor prognosis.
- 27. Prostatic acid phosphatase and prostate-specific antigen expression can be detected. In men with unknown prostatic acid phosphatase–positive and prostate- specific antigen positive metastatic carcinoma, salivary duct carcinoma should be included in the differential diagnosis in addition to prostatic adenocarcinoma. CK7 and HMWKs are helpful.
- 28. Markers for Salivary Gland Tumors With Oncocytic Differentiation MEC EMC ACC OC/OCA SDC p63 + +outer layer _ + peripheral _ Calponin/ SMA/SM MHC _ +outer layer _ _ _ CK7/CAM 5.2 _ + inner layer + + + AR _ _ _ _ + SOX10 _ + + _ _
- 30. Malignant biphasic epithelial tumor composed of modified myoepithelial and ductal cells. Both ductal and myoepithelial/basal cell markers, such as CK7, CAM 5.2, calponin, SMA, SMMHC, p63, SOX10, and S100. Most adenoid cystic carcinomas showed strong and diffuse expression of c-KIT
- 31. Overexpression of Ki-67 and p5 associated with poor prognosis. A recurrent t(6;9)(q22-23;p23-24) translocation identified in adenoid cystic carcinoma. This leads to the fusion of MYB and NFIB.
- 33. Expresses CK AE1/3, CAM 5.2, 34bE12, EMA, p53, p63, vimentin, bcl-2, S100. Overlapping histologic features with pleomorphic adenoma/canalicular adenoma and adenoid cystic carcinoma (especially in small biopsies).
- 34. Differentiation of Adenoid Cystic Carcinoma, Polymorphous Low-Grade Adenocarcinoma, and Pleomorphic Adenoma c-KIT Calponi n/SMA CK7 MIB-1 PLGA1 GFAP PA -/+ + + luminal <5% + + PLGA -/+ - + all cells <5% - - AdCC + + + luminal cells > 10% - -